Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 14/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | CDC25A | P30304 | 1/20 | 0.45 |
| ▸ | CDC25C | P30307 | 1/20 | 0.45 |
| ▸ | TYMS | P04818 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6508962 | 0.83 | CHEK1 (0.74) | CHEK1CYP1A2GAA | |
| SCHEMBL6514882 | 0.83 | CHEK1 (0.74) | CHEK1CSF1RCDC25ACDC25CTYMS | |
| SCHEMBL6046750 | 0.83 | CHEK1 (0.74) | CHEK1CSF1RTYMS | |
| SCHEMBL6509924 | 0.82 | CHEK1 (0.70) | CHEK1CSF1RLMNACYP1A2GAA | |
| Hydrochloric Acid SCHEMBL6508722 | 0.82 | CHEK1 (0.72) | CHEK1CSF1RCDC25ACDC25CTYMS | |
| SCHEMBL6509801 | 0.79 | CHEK1 (0.67) | CHEK1CSF1RLMNA | |
| SCHEMBL6507557 | 0.77 | CHEK1 (0.62) | CHEK1CSF1RLMNACYP1A2GAA | |
| SCHEMBL4006355 | 0.77 | CHEK1 (1.00) | CHEK1GAAHPGD | |
| SCHEMBL6513915 | 0.76 | CHEK1 (0.60) | CHEK1CSF1RLMNACYP1A2GAA | |
| SCHEMBL6507672 | 0.76 | CHEK1 (0.60) | CHEK1CSF1RLMNACYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005014588-A1 | SUBSTITUTED THIENYL-HYDROXAMIC ACIDS HAVING HISTONE DEACETYLASE ACTIVITY | ARGENTA DISCOVERY LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | CHEK1 3/4885CSF1R 858/4885LMNA 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.